* For eligible 3rd party insured patients only and limited to a maximum co-pay value of $200.00.
References
1. SOMA [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2007
2. Data on file. Meda Pharmaceuticals Inc.
Important Safety Information
SOMA® (carisoprodol) is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions
in adults. SOMA should be used for short periods (up to two to three weeks)
because adequate evidence of effectiveness for more
prolonged use has not been established and because
acute, painful musculoskeletal conditions are generally
of short duration.
Since the effects of SOMA and CNS depressants
(including alcohol) or psychotropic drugs may be
additive, appropriate caution should be exercised with
patients who take more than one of these agents
simultaneously. In postmarking experience with SOMA,
cases of dependence, withdrawal, and abuse have been
reported with prolonged use. SOMA should be used with
caution in addiction-prone patients. There have been
postmarketing reports of seizures in SOMA treated
patients with most cases having occurred in the setting
of multiple drug overdoses.
Most common side effects of SOMA include drowsiness, dizziness, and headache.
Please see full Prescribing Information.
You are encouraged to report negative side effects
of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
SOMA® 250 mg is manufactured by Meda Pharmaceuticals Inc.
Contact Meda | Privacy Policy | Site Map
Copyright ©2009 Meda Pharmaceuticals Inc. All rights reserved.
